research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
Search
for
Sort by
Research
90-120 / 414 results 
research Good Efficacy Achieved by Baricitinib in the Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis with Alopecia Areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Alopecia Areata: Genetic and Immunological Insights
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Ruxolitinib Found to Cause Eyelash Growth: A Case Report
Ruxolitinib treatment may cause eyelash growth.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Profile of Tofacitinib Citrate and Its Potential in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
research Novel Therapies for Alopecia Areata: The Era of Rational Drug Development
New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients With APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Current and Future Pharmacotherapy for Alopecia Areata
New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
research Past, Present, and Future Treatment of Alopecia Areata
More research is needed to find the best long-term treatments for Alopecia Areata.
research MTOR Signaling in Hair Follicle and Hair Diseases: Recent Progress
The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research The Role of Lymphocytes in the Development and Treatment of Alopecia Areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.